Navigation Links
AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease
Date:7/16/2009

LONDON, July 16 /PRNewswire-FirstCall/ -- AstraZeneca and The Mental Health Research Institute in Melbourne, Australia, today announced that they have entered into a research collaboration agreement to develop new ways of identifying Alzheimer's disease patients at early stages of the disease.

Researchers aim to find out whether testing cognition at short intervals (every one to three months) over an eighteen-month period will make it possible to identify individuals just at the point at which they are beginning to suffer cognitive decline as a result of Alzheimer's disease.

The study will be conducted in conjunction with The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies.

Alzheimer's disease is a degenerative brain disease for which there is currently no definitive diagnostic tool. Doctors rely on their clinical judgment to diagnose the disease once it has become symptomatic, but the pathologic process very likely starts a few years beforehand.

Professor Paul Maruff, from the Mental Health Research Institute says, "When assessing cognitive function in an individual at risk for dementia on the first occasion, it is often difficult to determine whether their performance on cognitive tests has declined from some previously higher level. The repeated application of a set of brief and simple cognitive measures could therefore help to identify accurately the point when the onset of Alzheimer's disease was imminent in individual people. This could ultimately lead to a more personalized approach with more effective treatments being given to the right patients at the right time."

Dr Judith Jaeger, Director of Neuroscience Early Clinical Development at AstraZeneca adds, "We recognize that in a
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
3. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
4. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
5. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
6. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
7. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
8. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
9. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
10. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
11. AstraZenecas David Brennan Elected PhRMA Board Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 The market for botulinum neurotoxin ... years, owing to novel medical indications created and due ... aging societies where physical appearance is extremely valued. Although ... current competitors, new companies and technologies are setting ground ... will put the price of 1st-gen products under pressure, ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July ... minimally invasive procedure known as morcellation carries a risk of ... likelihood more clearly. Twenty-seven of every 10,000 women who ... of the procedure, researchers found, with the odds being highest ... a hysterectomy with morcellation use a power cutter to slice ...
(Date:7/22/2014)... Montreal, July 22, ... for a cigarette twice as often as smokers who are ... the hardest time shaking off the habit may have more ... Those insights were among the collective findings recently published in ... team of researchers based in part at Concordia University. , ...
(Date:7/22/2014)... 5i Sciences, a medical technology company focused ... Coye, M.D., M.P.H. to a role as Senior Consultant. ... the market introduction of innovative technologies that impact healthcare ... on strategies for building a successful commercial healthcare enterprise ... Coye is currently the Chief Innovation Officer of UCLA ...
(Date:7/22/2014)... Latin America Drilling fluid and Completion fluid Market Report defines ... Latin America with analysis and forecast of revenue. The drilling ... to grow from around $0.93 billion in 2013 to $1.45 ... given period. , Browse through the TOC of the Latin ... an idea of the in-depth analysis provided. This also provides ...
Breaking Medicine News(10 mins):Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:Extra exercise helps depressed smokers kick the habit faster 2Health News:5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Latin America Drilling Fluid & Completion Fluid Market is Expected to Reach $1.45 Billion in 2018 - New Report by MicroMarket Monitor 6
... ... for Employees, SACRAMENTO, Calif., Sept. 8 Kurt Wetzel lost ... is seeing decreased absenteeism and lower levels of stress and,burnout among ... a,partner. And a recent study shows that employers are seeing initial ...
... WASHINGTON, Sept. 8 Parents probably,wouldn,t have guessed, ... finds middle-school students enjoy soyfoods as much as ... enjoy with tasty,and nutritious soyfoods., A plate ... took popular,menu items, including macaroni & cheese, burgers, ...
... One million Swiss Francs (around $ 885 thousand, 400 ... the amount must be destined by the winners to research ... the 2008 Balzan Prize winners were announced today in a ... Roma "La Sapienza", for the Visual Arts since 1700, Thomas ...
... patients using proton pump inhibitor (PPI) drugs. The drugs are used ... as other stomach/intestinal issues including ulcers, gastroesophageal reflux disease (GERD), dyspepsia, ... ... Denver, CO (PRWEB) September 8, 2008 -- LegalView, the number ...
... half of older patients successfully treated for colorectal cancer ... of cancer. The study, appearing in the October 15, ... of the American Cancer Society, indicates poor compliance to ... , Patients who undergo potentially curative surgery for colorectal ...
... Leaders to, Join the Smokefree Air 2010 Challenge and ... 8 College students are,falling victim to aggressive tobacco ... according to a new report released today by the,American ... of the current status of,tobacco use and policies on ...
Cached Medicine News:Health News:'Live Well for Life' Benefits Companies and Workers 2Health News:'Live Well for Life' Benefits Companies and Workers 3Health News:'Live Well for Life' Benefits Companies and Workers 4Health News:Back to School With Soy 2Health News:Balzan Foundation announced 2008 prize winners 2Health News:Balzan Foundation announced 2008 prize winners 3Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 2Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 3Health News:LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug 4Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 3Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 4
(Date:7/22/2014)... , July 22, 2014 The ... physicians is spreading to previously rep-friendly specialties, according ... sales and marketing consulting firm ZS Associates.      ... than 200 U.S. pharmaceutical sales teams. The report ... prescribers meet with the pharmaceutical sales reps who ...
(Date:7/22/2014)... July 22, 2014  Pressure BioSciences, Inc. ... Parabase Genomics ("Parabase"), (together "the companies"), today ... research and development agreement (the "collaboration"). Under ... develop a front-end, sample preparation method for ... confirmatory testing process. The sample preparation method ...
(Date:7/22/2014)... 2014 Glide ... on solid dose formulations of therapeutics and vaccines, ... octreotide acetate achieved successful results in a pre-clinical ... liquid product (Sandostatin®).  Based on these results, the ... to a contract manufacturing organisation (CMO), and to ...
Breaking Medicine Technology:Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... Corp. (NYSE: CFN ), a leading, global medical ... Sept. 30, 2010. "Our adjusted EPS results for ... highlighted a strong quarter for our Infusion, Dispensing, Infection Prevention ... of CareFusion. "In the first quarter we essentially overcame $60 ...
... 2, 2010 Elekta,s MOSAIQ® Oncology PACS has evolved ... image and data management solution for oncology professionals that ... information and address the requirements of the modern oncology ... System (OIS), MOSAIQ Data Director transforms the patient ...
Cached Medicine Technology:CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 2CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 3CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 4CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 5CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 6CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 7CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 8CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 9CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance 10Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology 2Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology 3Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology 4
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Designated most popular model or size. 3 mm tip....
Medicine Products: